Vancouver General Hospital
Vancouver, British Columbia, V5Z1M9, Canada
Location status: Recruiting
NCT Number: NCT07423936
The aim of this study is to demonstrate that cerebral blood flow and brain function do not resume after death declaration in organ donors who undergo normothermic regional perfusion to restore organ function following death determination by circulatory criteria, when appropriate safeguards are applied.
To assess the absence of cerebral perfusion and function, investigators will use continuous and comprehensive multimodal neuromonitoring throughout the withdrawal of life-sustaining therapies, the dying process and the NRP procedure.
Interested in participating?
Request Info19 year and older
All sexes
Observational
Vancouver, British Columbia, V5Z1M9, Canada
Location status: Recruiting
This will be a proof-of-concept study aimed at establishing the feasibility of multimodal neuromonitoring in patient undergoing abdominal (A-NRP) and thoraco-abdominal (TA-NRP) and to investigate whether resumption of CBF or function occurs in a cohort of DCD organ donors during A-NRP and TA-NRP. A central goal of this study is to demonstrate the absence of cerebral blood flow and function following normothermic regional perfusion, thereby improving clinical confidence to its safety and maintenance of adherence to death determination in organ donors.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Neuromonitoring during withdrawal of life sustaining therapies, dying process and during normothermic regional perfusion after death.
The neuromonitoring will include:
Time frame: One hour prior to withdrawal of life-sustaining therapies, during the dying duration and for 2 hours during normothermic regional perfusion
To determine the presence or absence of the brain circulation and function during normothermic regional perfusion assessed by intra-parenchymal neuromonitoring, non-invasive neuromonitoring and clinical examination.
Reperfusion or regain of brain function during normothermic regional perfusion will be expressed in proportion.
Restoration of either cerebral perfusion or neurological function in a patient will be considered a single brain reanimation event.
Clinical examination will consist of serial pupillary light reflex assessment and monitoring for respiratory efforts during normothermic regional perfusion.
Evidence of brain function will be determined by the presence of rhythmic delta wave activity on electroencephalography, N20 response with somatosensory evoked potentials or presence of brainstem auditory evoked potentials.
Restoration of brain circulation will be determined by the presence of cerebral blood flow (>10mls/100g/min) or brain tissue oxygen tension (>2mmHg).
Time frame: One hour prior to withdrawal of life-sustaining therapies, during the dying duration and for 2 hours during normothermic regional perfusion
To assess the feasibility of implementing multimodal neuromonitoring in DCD organ donors undergoing normothermic regional perfusion.
This will be a descriptive outcome in which investigators will calculate the duration of available data for each modality and compare it with the total observation period.
The investigators hypothesized that feasibility will be strong and that > 80% data variables will be collected for the pre-specified duration in each case.
Time frame: During normothermic regional perfusion
To assess the agreement between invasive (intra-parenchymal cerebral blood flow, intra-parenchymal brain oxygenation, invasive EEG) and non invasive neuromonitoring (transcranial doppler, surface EEG, brainstem auditory evoked potentials, somatosensory evoked potentials) in determining the presence of brain circulation and function during normothermic regional perfusion
Contact information is provided by the study sponsor or research team.
University of British Columbia
Other
Multimodal NeurOmonitoring During NormOthermic Regional PerFusion for Organ Donors Determined Dead by CircuLatory Criteria fOllowing Withdrawal of Life Sustaining Measures (NONOFLOW): A Proof-of-Concept Study
Acronym: NONOFLOW
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03051464
Colorectal Neoplasms, Digestive System Diseases
Dallas, Texas, United States
View Trial DetailsNCT06758830
Chemoradiotherapy, Chemotherapy
Vilnius, Lithuania
View Trial DetailsNCT06982404
Biopsy, Gene Expression Profiling
Vienna, State of Vienna, Austria
View Trial DetailsNCT05772923
Colorectal Neoplasms, Digestive System Diseases
Nijmegen, Gelderland, Netherlands
View Trial Details